The company focuses on providing a minimally invasive and non-opioid treatment option for individuals with chronic neuropathic pain. Credit: Engin Akyurt from Pixabay.

US-based Nalu Medical has raised $65m in a Series E financing round to further the development and commercialisation of its neurostimulation system for chronic pain treatment.

The funding will primarily accelerate commercial growth and expand clinical and health-economic evidence for the Nalu system, which features the micro-implantable pulse generator (micro-IPG).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Series E financing round was led by Novo Holdings. It also saw participation from all existing major investors including Aperture Venture Partners, Gilde Healthcare, MVM Partners, and Pura Vida.

Novo Holdings Venture Investments team partner Eric Snyder said: “The differentiated Nalu neurostimulation product has the potential to benefit millions of patients suffering from chronic neuropathic pain.

“We are impressed with their growing body of clinical evidence demonstrating meaningful clinical results in both the emerging market for peripheral nerve stimulation (PNS) and in the established market of spinal cord stimulation (SCS).”

Nalu Medical will also use the proceeds from the round to continue product development and enhance operations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company focuses on providing a minimally invasive and non-opioid treatment option for individuals with chronic neuropathic pain.

Nalu Medical president and CEO Tom West said: “The Nalu team is excited about meaningfully expanding and improving the treatment options in the peripheral nerve pain space by setting a new standard of care while also offering a disruptive, minimally invasive, solution in the established spinal cord stimulation market.

“We continue to invest in building clinical data to expand access for patients who often don’t have other therapeutic options.”

In June 2023, Nalu Medical announced the enrolment of the first patient in its COMFORT-2 PNS randomised controlled study for a micro-implantable pulse generator.